Guru Fundamental Report for JNJ

Validea's guru fundamental report assigns Johnson & Johnson (JNJ) a 77% rating using the Partha Mohanram P/B Growth Investor model, positioning it just below the 80% threshold for investment interest. This model, recognized for identifying high-performing growth stocks, evaluates JNJ as a large-cap growth stock in the Biotechnology & Drugs sector. While JNJ passed most underlying fundamental tests, it notably failed criteria related to Advertising to Assets and Research and Development to Assets, critical factors for sustained growth in its industry.

Analysis

Johnson & Johnson (JNJ) receives a moderately positive evaluation based on Validea's Partha Mohanram P/B Growth Investor model, scoring 77%. This places the stock just below the 80% threshold that typically indicates investment interest from this specific quantitative strategy. The model, designed to identify sustainable growth among low book-to-market stocks, classifies JNJ as a large-cap growth name within the Biotechnology & Drugs industry. The company exhibits strong underlying fundamentals, passing key tests for Return on Assets (ROA), Cash Flow from Operations to Assets, and stability metrics such as ROA Variance and Sales Variance. However, the model flagged two significant weaknesses: JNJ failed the criteria for both Advertising to Assets and Research and Development to Assets. For a firm in its sector, where R&D is a critical driver of future product pipelines and long-term growth, this specific failure warrants close attention and likely prevents the stock from achieving a higher score under this growth-oriented framework.

Key Decisions for Investors

• Investors should recognize the mixed signal on Johnson & Johnson: its strong current financial health, evidenced by passing cash flow and return on asset metrics, is contrasted by potential weaknesses in its long-term growth drivers.
• Given the model's specific flags on R&D and advertising investment levels, investors focused on sustainable growth should conduct further due diligence on the productivity of JNJ's R&D pipeline and the efficiency of its marketing spend relative to peers.
• The 77% score, being just shy of the model's 80% interest threshold, suggests that while not a strong buy signal for aggressive growth portfolios, JNJ may warrant consideration for investors seeking stable, large-cap exposure with solid, albeit not exceptional, growth characteristics.